On May 28, 2022 FORUS reported that it was a proud sponsor and participant in the Défi Cyclo-Myélome (Press release, FORUS Therapeutics, MAY 28, 2022, View Source;utm_medium=rss&utm_campaign=forus-was-a-proud-sponsor-and-participant-in-the-defi-cyclo-myelome-on-may-28th-2022 [SID1234615259]). This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada Chair, held by Dr. Richard LeBlanc, at the Université de Montréal at Maisonneuve-Rosemont Hospital (HMR). Funds from this event will support research focused on improving the care of individuals living with multiple myeloma. Special recognition to Marie-Josèphe Champagne who rode on behalf of FORUS alongside other supporters, patients, caregivers and healthcare professionals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 27, 2022 RemedyBio reported a new collaborative research project with the Thoracic Oncology Research Group (TORG) at the Trinity St James Cancer Institute (TSJCI) to identify novel predictive biomarkers for Non-Small Cell Lung Cancer (Press release, Remedy Biologics, MAY 27, 2022, View Source [SID1234644113]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The outputs from this partnership are intended to lay the foundations for next generation diagnostic and prognostic products that could fundamentally change the provision of cancer care.
We are excited to collaborate closely with the talented Trinity & St James’ thoracic team. Despite recent breakthrough advances in the treatment of lung cancer, a huge unmet medical need remains in terms of early detection, minimally invasive monitoring for cancer recurrence and improved precision of patient stratification. This requires us to look at how new and established tools can be best integrated to benefit patients so that they can receive the best medicines for them at the right time. RemedyBio’s transformative immune discovery platform, Nanoreactor, will establish an immune profile for each patient allowing a profound understanding of the interaction between immune, disease, and therapeutic effects.
Dr Colm Galligan, Chief Medical Officer, RemedyBio
We are delighted to collaborate with RemedyBio to advance our translational thoracic oncology research programme at the TSJCI. The immune profiling of lung tumours, using the innovative Nanoreactor, represents a promising approach to improve patient stratification and increase the clinical efficacy of cancer immunotherapy. The group is excited to work with RemedyBio on multiple integrated and truly innovative projects with the potential for near term patient benefit and clinical impact.
Dr Kathy Gately & Prof Stephen Finn, Trinity College Dublin/ St James’ Hospital
We are grateful to Enterprise Ireland for supporting this project through its Innovation Partnership Programme

On May 27, 2022 NEX-I reported the company has established 20 types of mouse models for refractory factors, and developed ‘NX-101,’ a candidate for an immunotherapy agent targeting solid tumors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=18&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643435]). "We plan to complete non-clinical trials within next year and enter phase 1 clinical trials in the fourth quarter of next year."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NEX-I was founded in April last year by CEO Kyung-Wan Yoon, who served as Chief Scientific Officer (CSO) and Vice President at Genome & Company. Currently, about 15 people are working at Nexi, including Chief Operating Officer (COO) Vice President Son Jin-beop, and Chief Technology Officer (CTO) Professor Kim Tae-woo of Korea University, who are former DM Bio employees, and plans to add about 10 more people this year.

NexI was selected for the TIPS and Korea New Drug Development Foundation (KDDF) ​​project last year, and attracted 4 billion won in pre-Series A. In particular, we will cooperate in the mid- to long-term with Daewoong Pharmaceutical, which participated as a strategic investor in Pre Series A, to develop pipelines such as non-small cell lung cancer (NSCLC) antibody candidate ‘NXI-101’ and metastatic melanoma antibody candidate ‘NXI-201’. We plan to continue research and development.

On May 27, 2022 NEXI, is focusing on developing next-generation immunotherapy drugs, reported the company won 4 billion for Pre-A funding (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=17&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643434]). D.S.C.investment,Schmidt,Hana Ventures,Daewoong Pharmaceutical and others participated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DSCSchmidt, a subsidiary of Investment, has8We helped select the TIPS project along with the monthly seed investment.,Participated in this follow-up investment as well..

Daewoong Pharmaceutical is a strategic investor and plans to seek cooperation measures such as joint research with NexI in the future..

Kim YohanDSCHead of Investment Biotech Division"Although there are differences depending on the cancer type, the response rate of existing immunotherapy drugs is20~30%There is an unmet medical need for this due to low severity..Nexi decided to make this investment because it fits this global development trend."He said.

Pre-AThe investment is for NexI’s next-generation immuno-anticancer drug pipeline.’NXI-101’class’NXI-201’It will be used for research and development of.

Kyung-wan Yoon, CEO of Nexi"With this investment, we will actively recruit excellent talent and accelerate research and development of anti-cancer drugs..We will do our best for overseas partnering starting next year."said.

The company said"Based on its independently built platform technology, Nexi has discovered a number of factors that induce anti-cancer immunotherapy drug refractoriness.,targeting thisFirst-in-classDeveloping new antibody drugs"as"We plan to administer it alone or in combination to cancer patients who do not respond to immunotherapy.,Through this, we will overcome the limitations of low response rates of existing immunotherapy drugs."He said.

Nexi announced earlier this monthNXI-101Established by being selected for national new drug development project through research8After about a month4Has been selected for 10 national projects.

On May 27, 2022 Daewoong Pharmaceutical reported on the 23rd that it signed a business agreement (MOU) with Nexi, a bio venture specializing in new drug development, for joint research and development of immunotherapy anti-cancer drugs and mid- to long-term cooperation (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=16&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643433]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the announcement, NexI is developing new antibody drugs by targeting new immunotherapy refractory factors based on its proprietary platform technology. We plan to develop treatments alone or in combination with existing immunotherapy agents for cancer patients who cannot use immunotherapy agents or who do not respond to existing anticancer agents.

Through this agreement, Daewoong Pharmaceutical and NexI plan to jointly research and develop NexI’s pipeline, including the non-small cell lung cancer (NSCLC) antibody candidate ‘NXI-101’ and the metastatic melanoma antibody candidate ‘NXI-201’.

In particular, Daewoong Pharmaceutical plans to participate as a strategic investor (SI) in NexI’s Pre-A series investment, cooperate with NexI in overseas licensing out, and build various business models through mid- to long-term cooperation.

Seung-ho Jeon, CEO of Daewoong Pharmaceutical, said, "It is encouraging to be able to cooperate in the field of research and development with NexI, whose excellent technology has been proven through selection as a national project." He added, "We will continue to research innovative new drugs in the field of immunotherapy through open collaboration, which is Daewoong Pharmaceutical’s research and development strategy. "I will focus on this," he said.

Kyung-wan Yoon, CEO of Nexi, said, "We are pleased to have entered into a cooperative relationship with Daewoong Pharmaceutical," and added, "We will strive to achieve innovative results in the field of new immunotherapy drug development through close cooperation between the two companies in the future."